Windtree Therapeutics, Inc.

3.45 USD
+0.46 (+15.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Windtree Therapeutics, Inc. stock is down -25% since 30 days ago. The next earnings date is Jun 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20.69% of the previous 28 June’s closed higher than May.

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trials for heart failure, and AEROSURF, an aerosolized KL4 surfactant.